204 related articles for article (PubMed ID: 22205686)
1. Blocking epidermal growth factor receptor activation by 3,3'-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo.
Kandala PK; Wright SE; Srivastava SK
J Pharmacol Exp Ther; 2012 Apr; 341(1):24-32. PubMed ID: 22205686
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Janus-activated kinase-2 (JAK2) by diindolylmethane in ovarian cancer in vitro and in vivo.
Kandala PK; Srivastava SK
Drug Discov Ther; 2012 Apr; 6(2):94-101. PubMed ID: 22622019
[TBL] [Abstract][Full Text] [Related]
3. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3).
Kandala PK; Srivastava SK
BMC Med; 2012 Jan; 10():9. PubMed ID: 22280969
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of combined platelet-activating factor receptor and epidermal growth factor receptor targeting in ovarian cancer cells.
Yu Y; Zhang M; Zhang X; Cai Q; Hong S; Jiang W; Xu C
J Hematol Oncol; 2014 May; 7():39. PubMed ID: 24886678
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of EGFR-AKT axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model.
Loganathan S; Kandala PK; Gupta P; Srivastava SK
PLoS One; 2012; 7(8):e43577. PubMed ID: 22952709
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Ali S; Banerjee S; Ahmad A; El-Rayes BF; Philip PA; Sarkar FH
Mol Cancer Ther; 2008 Jun; 7(6):1708-19. PubMed ID: 18566242
[TBL] [Abstract][Full Text] [Related]
7. Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells.
Kandala PK; Srivastava SK
Mol Pharmacol; 2010 Aug; 78(2):297-309. PubMed ID: 20444961
[TBL] [Abstract][Full Text] [Related]
8. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract][Full Text] [Related]
9. Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK.
Kandala PK; Srivastava SK
Oncotarget; 2012 Apr; 3(4):435-49. PubMed ID: 22564965
[TBL] [Abstract][Full Text] [Related]
10. Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis.
Peng Z; Raufman JP; Xie G
PLoS One; 2012; 7(10):e48461. PubMed ID: 23119029
[TBL] [Abstract][Full Text] [Related]
11. NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts.
Selvendiran K; Bratasz A; Tong L; Ignarro LJ; Kuppusamy P
Cell Cycle; 2008 Jan; 7(1):81-8. PubMed ID: 18196976
[TBL] [Abstract][Full Text] [Related]
12. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
13. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
15. A potential peptide therapeutic derived from the juxtamembrane domain of the epidermal growth factor receptor.
Boran AD; Seco J; Jayaraman V; Jayaraman G; Zhao S; Reddy S; Chen Y; Iyengar R
PLoS One; 2012; 7(11):e49702. PubMed ID: 23166750
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
Ohta T; Ohmichi M; Shibuya T; Takahashi T; Tsutsumi S; Takahashi K; Kurachi H
Cancer Biol Ther; 2012 Apr; 13(6):408-16. PubMed ID: 22313686
[TBL] [Abstract][Full Text] [Related]
17. 3,3'-Diindolylmethane suppresses the growth of gastric cancer cells via activation of the Hippo signaling pathway.
Li XJ; Park ES; Park MH; Kim SM
Oncol Rep; 2013 Nov; 30(5):2419-26. PubMed ID: 24008339
[TBL] [Abstract][Full Text] [Related]
18. Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo.
Chen D; Banerjee S; Cui QC; Kong D; Sarkar FH; Dou QP
PLoS One; 2012; 7(10):e47186. PubMed ID: 23056607
[TBL] [Abstract][Full Text] [Related]
19. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
20. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
[Next] [New Search]
